Skip to main content
Top
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

Promoter hypermethylation of the cysteine protease RECK may cause metastasis of osteosarcoma

Authors: Leisheng Wang, Junbo Ge, Tian Ma, Yanpin Zheng, Shiqiao Lv, Yu Li, Shaoxian Liu

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

The present study examined the role of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) promoter hypermethylation as a causative factor in metastasis of osteosarcoma. Using human pathological samples, it is demonstrated that RECK, a cysteine protease that reversibly regulates expression of matrix metalloproteases like matrix metallopeptidase 9 (MMP9), is transcriptionally inhibited in osteosarcoma, especially metastatic variants. This result comes from its promoter hypermethylation, as evaluated in the present study by methylation-specific PCR reaction. The expression of RECK was also significantly diminished in the metastatic variants of osteosarcoma. This downregulation of RECK in advanced grades of osteosarcoma and metastatic grades was also associated with the increased expression of invadosome-specific markers like MMP9, phospho-FAK, and integrins, suggesting the complex contributions of RECK in the prevention of metastasis and its downregulation as a causative factor in osteosarcoma metastasis.
Literature
1.
go back to reference Chang L, Asatrian G, Dry SM, James AW. Circulating tumor cells in sarcomas: a brief review. Med Oncol. 2015;32:430.CrossRefPubMed Chang L, Asatrian G, Dry SM, James AW. Circulating tumor cells in sarcomas: a brief review. Med Oncol. 2015;32:430.CrossRefPubMed
2.
go back to reference Kim SS, Park YK. Significance of MTA1 in the molecular characterization of osteosarcoma. Cancer Metastasis Rev. 2014;33:981–91.CrossRefPubMed Kim SS, Park YK. Significance of MTA1 in the molecular characterization of osteosarcoma. Cancer Metastasis Rev. 2014;33:981–91.CrossRefPubMed
3.
4.
go back to reference Yang G, Yuan J, Li K. EMT transcription factors: implication in osteosarcoma. Med Oncol. 2013;30:697.CrossRefPubMed Yang G, Yuan J, Li K. EMT transcription factors: implication in osteosarcoma. Med Oncol. 2013;30:697.CrossRefPubMed
5.
go back to reference Li H, Zhang K, Liu LH, Ouyang Y, Bu J, Guo HB. A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma. Tumour Biol. 2014;35:5487–91.CrossRefPubMed Li H, Zhang K, Liu LH, Ouyang Y, Bu J, Guo HB. A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma. Tumour Biol. 2014;35:5487–91.CrossRefPubMed
6.
go back to reference Poudel B, Kim DK, Ki HH, Kwon YB, Lee YM, Kim DK. Downregulation of ERK signaling impairs U2OS osteosarcoma cell migration in collagen matrix by suppressing MMP9 production. Oncol Lett. 2014;7:215–8.PubMed Poudel B, Kim DK, Ki HH, Kwon YB, Lee YM, Kim DK. Downregulation of ERK signaling impairs U2OS osteosarcoma cell migration in collagen matrix by suppressing MMP9 production. Oncol Lett. 2014;7:215–8.PubMed
7.
go back to reference Sun D, Wang X, Zhang H, Deng L, Zhang Y. MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int. 2011;35:569–74.CrossRefPubMed Sun D, Wang X, Zhang H, Deng L, Zhang Y. MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int. 2011;35:569–74.CrossRefPubMed
8.
go back to reference Clark JC, Akiyama T, Thomas DM, Labrinidis A, Evdokiou A, Galloway SJ, et al. RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model. Cancer. 2011;117:3517–28.CrossRefPubMed Clark JC, Akiyama T, Thomas DM, Labrinidis A, Evdokiou A, Galloway SJ, et al. RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model. Cancer. 2011;117:3517–28.CrossRefPubMed
9.
go back to reference Xu J, Wu S, Shi X. Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma. J Orthop Res. 2010;28:1621–5.CrossRefPubMed Xu J, Wu S, Shi X. Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma. J Orthop Res. 2010;28:1621–5.CrossRefPubMed
10.
go back to reference Kang HG, Kim HS, Kim KJ, Oh JH, Lee MR, Seol SM, et al. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. J Orthop Res. 2007;25:696–702.CrossRefPubMed Kang HG, Kim HS, Kim KJ, Oh JH, Lee MR, Seol SM, et al. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. J Orthop Res. 2007;25:696–702.CrossRefPubMed
11.
go back to reference Zhang C, Ling Y, Zhang C, Xu Y, Gao L, Li R, et al. The silencing of RECK gene is associated with promoter hypermethylation and poor survival in hepatocellular carcinoma. Int J Biol Sci. 2012;8:451–8.CrossRefPubMedPubMedCentral Zhang C, Ling Y, Zhang C, Xu Y, Gao L, Li R, et al. The silencing of RECK gene is associated with promoter hypermethylation and poor survival in hepatocellular carcinoma. Int J Biol Sci. 2012;8:451–8.CrossRefPubMedPubMedCentral
12.
go back to reference Lu XX, Zhang SM, Fang Y, Wang ZT, Xie JJ, Zhan Q, et al. Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma. Tumour Biol. 2013;34:3339–43.CrossRefPubMed Lu XX, Zhang SM, Fang Y, Wang ZT, Xie JJ, Zhan Q, et al. Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma. Tumour Biol. 2013;34:3339–43.CrossRefPubMed
13.
go back to reference Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25:398–406.CrossRefPubMed Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25:398–406.CrossRefPubMed
14.
go back to reference Noda M, Rodan GA. Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins. Connect Tissue Res. 1989;21:71–5.CrossRefPubMed Noda M, Rodan GA. Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins. Connect Tissue Res. 1989;21:71–5.CrossRefPubMed
15.
go back to reference Baptista AM, Camargo AF, Filippi RZ, Oliveira CR, Azevedo Neto RS, Camargo OP. Correlation between the expression of VEGF and survival in osteosarcoma. Acta Ortop Bras. 2014;22:250–5.CrossRefPubMedPubMedCentral Baptista AM, Camargo AF, Filippi RZ, Oliveira CR, Azevedo Neto RS, Camargo OP. Correlation between the expression of VEGF and survival in osteosarcoma. Acta Ortop Bras. 2014;22:250–5.CrossRefPubMedPubMedCentral
Metadata
Title
Promoter hypermethylation of the cysteine protease RECK may cause metastasis of osteosarcoma
Authors
Leisheng Wang
Junbo Ge
Tian Ma
Yanpin Zheng
Shiqiao Lv
Yu Li
Shaoxian Liu
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3688-4

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine